Tuesday, November 17, 2026

Open Innovation|Creating greater value through collaboration, Sanshin Open Innovation

Sanshin Pharmaceutical, which has expanded and relocated its research center to Magok-dong, Gangseo-gu, Seoul, to expand its advanced research facilities and strengthen its R&D infrastructure based on sustained R&D investment, is hosting an accelerator program. We are looking for startups who can collaborate and grow together with us as we make the leap to become a global pharmaceutical company. The deadline for applications is August 18.

What is the background of the co-creation program?

Based on its sustained R&D investment, Sangsin Pharmaceutical has expanded and relocated its research center to Magok-dong, Gangseo-gu, Seoul Special City in 2021 in order to expand its advanced research facilities and strengthen its R&D infrastructure. The newly reborn Sangsin Pharmaceutical Research Center is expected to become a C&D center (connected collaboration and development center) for new drug development through a large-scale expansion of its research infrastructure including excellent human resources and all-round open innovation with domestic and overseas research institutions and pharmaceutical biotech companies that have technological competitiveness. It will function as a C&D center (connected collaboration and development center) for new drug development through all-round open innovation with domestic and international research institutions and pharmaceutical biotech companies with competitive technologies.
Through this, Sanshin Pharmaceutical Research Center will develop innovative global new drugs and source technologies for unmet medical needs and lead Sanshin Pharmaceutical's quantum jump to a global pharmaceutical company.
We look forward to receiving proposals from startups with excellent technology that we can collaborate with and grow with as Sanshin Seiyaku makes the leap to becoming a global pharmaceutical company. Thank you very much.

Outline of "Sanshin Pharmaceutical Co.

▶︎ Application deadline: Sunday, August 18, 2024 23:00
▶︎ Target companies: all domestic and international startups. Any industry.
▶︎ Participation fee: Free
▶︎ Sponsored by Sanshin Pharmaceutical Co.

What we want to achieve with the Co-Creation Program

1. antibody-based new drug development technology

  • Sanshin Pharmaceutical was founded with the dignity of human life as its corporate spirit. To protect human health through the development of new drugs and to eradicate diseases at their root, Sanshin Pharmaceutical is constantly challenging itself to develop superior drugs. Based on these beliefs, we are looking for startups with ideas that we can collaborate with.
  • Desired Collaboration
  1. Human Antibody Library Production Technology
  2. Antibody Discovery Technology
  3. Antibody Engineering Technology
  4. Antibody Optimization Technology
  5. Double and triple antibody production technology
  6. Antibody culture/purification/analysis technology
  7. ADC and dual specific ADC fabrication technology
  8. Various other antibody-related ideas

2. new drug development technology based on small molecule compounds

  • Desired Collaboration
  1. Research and development of innovative small molecule anti-cancer drugs
  2. Research and development of innovative small molecule fibrosis treatments
  3. Research and development of small molecule innovative allergy treatments
  4. ADC Linker Technology
    *Linker technology development, linker drug binding technology, stability evaluation, manufacturing and production technology, etc.
  5. TPD Development Technology
    Protein degradation target discovery and validation technology, molecular glue-PROTAC design technology, TPD synthesis and optimization technology, etc.
  6. Other low-molecular-weight compound-based therapeutic agents or related technologies

3. new drug development technology based on artificial intelligence

  • Desired Collaboration
  1. Artificial intelligence-based small molecule drug design platform
  2. Artificial intelligence-based protein new drug design platform
  3. AI-based new drug target discovery and validation technology
  4. AI-based drug screening and virtual simulation technologies and services
  5. Other technologies related to new drug development utilizing AI

Sanshin Seiyaku's management resources (resources) that startups can utilize

Provision of office space in the Asatani Research Center and use of its equipment

Offices provided in the Asatani Research Center
Provision of welfare at the level of Sanjin employees (breakfast - lunch provided, exercise facilities and other welfare facilities provided)
Equipment available at the Asatani Research Center (NMR, MPLC, HPLC, LC-MS/MS, SPR, FACs, fluorescence microscope, SPF-grade animal room, fluidized bed granulator, dosing machine, hydrodynamic dryer, etc.)

interpoint (interword separation)Research funding support and SI investment through the National R&D Agenda

Research funding support through joint execution of national R&D projects
Strategic investment (SI) is possible due to the potential for technological growth
Collaboration with cooperating investment companies such as Asatani Weconomy Fund

Raw material pharmaceuticals and EU-GMP-grade injectable production facilities are available.

Utilizing the Gosong Plant and Konan Plant facilities, the company is able to produce raw material pharmaceuticals and EU-GMP-grade injectable drugs.

interpoint (interword separation)Advisory use of new drug development specialists available

Advisory access to professional personnel with specialized experience and knowledge of clinical, development, and marketing issues in the pharmaceutical sector

Sanshin Seiyaku's domestic and global network can be shared.

Global network can be shared through BIO-US/EU along with the Korea-US network

Enthusiasm for the Program

Sanshin Seiyaku and Creww Korea are looking for Japan's best startups to participate in the "Sanshin Seiyaku (Co., Ltd.) Open Innovation".
We look forward to receiving applications from startups who wish to grow with Sanshin Seiyaku through this program!

About Sanshin Pharmaceutical

"A company that pioneers healthy living for mankind with a creative spirit and moves forward for a prosperous future.

Established in 1968, Sanshin Pharmaceutical is a mid-sized Korean pharmaceutical company. The company has over 770 members and generates annual sales of approximately 300 billion won through the sale of over-the-counter drugs and specialty drugs in various medical fields.

The headquarters is located in Hongdae, Seoul, Republic of Korea, with factories in Osong, Chungcheongbuk-do, and Hyangnam, Gyeonggi-do, that produce raw material pharmaceuticals and finished products. The research center in charge of research and development of new drugs is located in Asagok, Seoul.

In December 2021, Sanshin Pharmaceutical completed construction of the Maya Research Center with a budget of 40 billion won. The Magok Research Center has the resources and capabilities to independently carry out the entire process of new drug development from the initial stage to the final clinical and licensing stages. It also has an in-house AI drug development team that actively utilizes AI in new drug development. Our focus areas are immuno-cancer, non-alcoholic steatohepatitis (MASH), and allergic diseases, and we are also conducting research on novel modalities of ADC (antibody-drug conjugate) and TPD (targeted proteolysis).

Through open innovation, the Asagaya Research Center has conducted joint research with more than 10 Korean and foreign venture companies since 2022.

We are looking forward to your support as we work together and grow as a global pharmaceutical company through the development of innovative new medicines.
https://www.samjinpharm.co.kr/front/en/main/index.asp

PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。